Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis

Clinical Research in Cardiology

Volumn 103, Issue 1, 2014, Pages 21-27

  Clever, Yvonne P ^a   Cremers, Bodo ^a   Von Scheidt, Wolfgang ^b   Böhm, Michael ^a   Speck, Ulrich ^c   Scheller, Bruno ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Compassionate use; Drug coated balloon; In stent restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; GLYCERYL TRINITRATE; HEPARIN; PACLITAXEL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BALLOON CATHETER; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMPASSIONATE USE; CORONARY ARTERY BYPASS GRAFT; DEATH; DRUG COATED BALLOON CATHETER; DRUG CONTRAINDICATION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IN-STENT RESTENOSIS; INSULIN DEPENDENT DIABETES MELLITUS; LOADING DRUG DOSE; MALE; MEDICAL HISTORY; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; REVASCULARIZATION; SMOKING; STENT THROMBOSIS; YOUNG ADULT;

AGED; CARDIAC CATHETERS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; COMPASSIONATE USE TRIALS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893046200     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-013-0617-7     Document Type: Article

References (53)

1. Gruntzig A (1978) Transluminal dilatation of coronary-artery stenosis. Lancet 1:263
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316:701-706
3. Morice MC, Serruys PW, Sousa JE et al (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780
4. Kastrati A, Mehilli J, Pache J et al (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030-1039
5. Stone GW, Moses JW, Ellis SG et al (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998-1008
6. Virmani R, Guagliumi G, Farb A et al (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701-705
7. Joner M, Finn AV, Farb A et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193-202
8. Iakovou I, Schmidt T, Bonizzoni E et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126-2130
9. Pfisterer M, Brunner-La Rocca HP, Buser PT (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48:2584-2591
10. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020-1029
11. Daemen J, Wenaweser P, Tsuchida K et al (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667-678
12. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989-997
13. Kastrati A, Mehilli J, von Beckerath N et al (2005) Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293:165-171
14. Mehilli J, Byrne RA, Tiroch K et al (2010) Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 55:2710-2716
15. Cosgrave J, Melzi G, Corbett S et al (2007) Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J 153:354-359
16. Airoldi F, Briguori C, Iakovou I et al (2006) Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Am J cardiol 97:1182-1187
17. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G (2004) Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110:810-814
18. Speck U, Scheller B, Abramjuk C et al (2006) Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 240:411-418
19. Cremers B, Speck U, Kaufels N et al (2009) Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost 101:201-206
20. Cremers B, Biedermann M, Mahnkopf D, Bohm M, Scheller B (2009) Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol 98:325-330
21. Albrecht T, Speck U, Baier C, Wolf KJ, Bohm M, Scheller B (2007) Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol 42:579-585
22. Wohrle J, Birkemeyer R, Markovic S et al (2011) Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Heart 97:1338-1342
23. Rittger H, Brachmann J, Sinha AM et al (2012) A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol 59:1377-1382
24. Scheller B, Hehrlein C, Bocksch W et al (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113-2124
25. Scheller B, Hehrlein C, Bocksch W et al (2008) Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 97:773-781
26. Unverdorben M, Vallbracht C, Cremers B et al (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119:2986-2994
27. Unverdorben M, Kleber FX, Heuer H et al (2010) Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol 99:165-174
28. Habara S, Mitsudo K, Kadota K et al (2011) Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovascular interventions 4:149-154
29. Ali RM, Degenhardt R, Zambahari R et al (2011) Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention 7(Suppl K):K83-K92
30. Scheller B, Clever YP, Kelsch B et al (2012) Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovascular interventions 5:323-330
31. Tepe G, Zeller T, Albrecht T et al (2008) Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 358:689-699
32. Werk M, Langner S, Reinkensmeier B et al (2008) Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 118:1358-1365
33. Navarese EP, Austin D, Gurbel PA et al (2013) Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. Clin Res cardiol 102:279-287
34. Wijns W, Kolh P, Danchin N et al (2010) Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 31:2501-2555
35. Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344-2351
36. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL (2006) Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151:1260-1264
37. Waksman R, Bhargava B, White RL et al (1999) Intracoronary radiation for patients with refractory in-stent restenosis: an analysis from the WRIST-crossover trial. Washington Radiation for In-stent Restenosis Trial. Cardiovasc Radiat Med 1:317-322
38. Waksman R (2012) Too early to call. Cardiovasc Revasc Med 13:157-158
39. Alfonso F, Perez-Vizcayno MJ, Dutary J et al (2012) Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis: results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv 5:728-737
40. Alli OO, Teirstein PS, Satler L et al (2012) Five-year follow-up of the sirolimus-eluting stents vs vascular brachytherapy for bare metal in-stent restenosis (SISR) trial. Am Heart J 163:438-445
41. Raber L, Magro M, Stefanini GG et al (2012) Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125:1110-1121
42. Iofina E, Langenberg R, Blindt R, Kuhl H, Kelm M, Hoffmann R (2006) Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Am J Cardiol 98:1022-1027
43. Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo H (2006) Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol 58:665-672
44. Scheller B, Speck U, Romeike B et al (2003) Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 24:1462-1467
45. Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G (2003) Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 42:1415-1420
46. Speck U, Cremers B, Kelsch B et al (2012) Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv 5:392-400
47. Scheller B (2011) Opportunities and limitations of drug-coated balloons in interventional therapies. Herz 36:232-240
48. Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX (2011) Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention 7:K61-K65
49. Wöhrle J, Zadura M, Möbius-Winkler S et al (2012) SeQuent please world wide registry: clinical results of SeQuent please paclitaxel coated balloon angioplasty in a large-scaled, prospective registry study. J Am Coll Cardiol 60(18):1733-1738
50. Vajda Z, Guthe T, Perez MA et al (2011) Neurovascular in-stent stenoses: treatment with conventional and drug-eluting balloons. AJNR 32:7-1942
51. Bonaventura K, Leber AW, Sohns C et al (2012) Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clin Res Cardiol 101:573-584
52. Dorenkamp M, Boldt J, Leber A et al (2013) Cost-Effectiveness of Paclitaxel-Coated balloon angioplasty in patients with Drug-Eluting stent restenosis. Clin Cardiol 36(7):407-413
53. Cassese S, Byrne RA, Ott I et al (2012) Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv 5:582-589